Boehringer Ingelheim Animal Health and Novozymes today announced a strategic collaboration to develop and commercialize probiotics for global poultry production. Boehringer Ingelheim will market and distribute Novozymes’ FloraMax® probiotic product f
Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline by adding an innovative preclinical program with the acquisition of Nerio Therapeutics
While stepping up its investments in R&D significantly, Boehringer Ingelheim achieved a solid business performance in 2020 despite the COVID-19 pandemic.
Exploring innovation in interstitial lung disease (ILD)
Interstitial lung disease (ILD) describes a group of over 200 lung disorders characterized by inflammation and scarring of the interstitium of the lungs.
Driving innovation through diversity and inclusion. Inclusive leaders and an inclusive organisation allow diversity to flourish. Diversity is the mix. Inclusion is making the mix work.
Vaccine design technologies have made huge advances in recent years. One of the newer categories of vaccine, vectored vaccines, is overcoming challenges that conventional vaccines do not meet.